Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

 
• By Sten Stovall
Retina
Novartis' Brolucizumab Shows Further Advantages In nAMD Trials Versus Aflibercept • Source: Shutterstock

More from Sensory

More from Therapeutic Category